Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
MCRB Seres Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: MCRB
Price (delayed)
$7.13
Market cap
$62.26M
P/E Ratio
0.81
Dividend/share
N/A
EPS
$8.76
Enterprise value
$84.29M
Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to
Highlights
Seres Therapeutics's net income has soared by 188% YoY
The equity has soared by 184% YoY
MCRB's revenue has dropped by 100% year-on-year
Seres Therapeutics's gross profit has shrunk by 100% YoY
Key stats
What are the main financial stats of MCRB
Market
Valuations
Earnings
Shares outstanding
8.73M
Market cap
$62.26M
Enterprise value
$84.29M
Price to earnings (P/E)
0.81
Price to book (P/B)
1.23
Price to sales (P/S)
N/A
EV/EBIT
1.1
EV/EBITDA
0.93
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$116.59M
Net income
$72.95M
EBIT
$76.4M
EBITDA
$90.27M
Free cash flow
-$86.82M
Per share
Balance sheet
Liquidity
EPS
$8.76
EPS diluted
$8.75
Free cash flow per share
-$9.98
Book value per share
$5.79
Revenue per share
$0
TBVPS
$18.86
Total assets
$164.18M
Total liabilities
$113.72M
Debt
$89.55M
Equity
$50.47M
Working capital
$34.76M
Debt to equity
1.77
Current ratio
2.11
Quick ratio
2.24
Net debt/EBITDA
0.24
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
36.3%
Return on equity
26,673.1%
Return on invested capital
39.1%
Return on capital employed
57.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MCRB stock price
How has the Seres Therapeutics stock price performed over time
Intraday
1.86%
1 week
1.13%
1 month
-25.96%
1 year
-66.68%
YTD
-57.1%
QTD
-49.07%
Financial performance
How have Seres Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$116.59M
Net income
$72.95M
Gross margin
N/A
Net margin
N/A
Seres Therapeutics's net income has soared by 188% YoY
MCRB's revenue has dropped by 100% year-on-year
Seres Therapeutics's gross profit has shrunk by 100% YoY
MCRB's operating income has dropped by 75% year-on-year but it is up by 3.9% since the previous quarter
Price vs fundamentals
How does MCRB's price correlate with its fundamentals
Growth
What is Seres Therapeutics's growth rate over time
Valuation
What is Seres Therapeutics stock price valuation
P/E
0.81
P/B
1.23
P/S
N/A
EV/EBIT
1.1
EV/EBITDA
0.93
EV/Sales
N/A
The EPS has soared by 172% YoY
The equity has soared by 184% YoY
MCRB's revenue has dropped by 100% year-on-year
Efficiency
How efficient is Seres Therapeutics business performance
Dividends
What is MCRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MCRB.
Financial health
How did Seres Therapeutics financials performed over time
The total assets is 44% higher than the total liabilities
MCRB's current ratio has soared by 124% QoQ and by 26% YoY
The quick ratio has soared by 122% QoQ and by 74% YoY
MCRB's debt is 77% greater than its equity
The equity has soared by 184% YoY
Seres Therapeutics's debt to equity has surged by 149% YoY but it has shrunk by 73% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.